Genmab (GMAB DC) Q3 2026 (USD): Darzalex sales 4.3bln

Darzalex is the long-standing royalty engine of the Genmab and Johnson & Johnson partnership: J&J books the product sales and Genmab takes a tiered royalty, so a single-figure headline of this kind is typically the most-watched line of the Danish company's print even though it is not Genmab revenue in the conventional sense. The analytical distinction worth drawing is between royalty momentum, which has historically compounded with multi-year persistence given the franchise's entrenched position across myeloma lines of therapy, and the longer-dated question of what replaces it, since the royalty stream is finite and the market has consistently valued Genmab on the bridge to its own pipeline and partnered assets. With a royalty line, the checks are mechanical: the J&J-reported sales figure reconciles against the royalty Genmab books, and any gap between the two tends to reflect tiering or timing rather than demand. The follow-ons are the J&J disclosure for confirmation of the underlying sales trend, the rest of the Genmab release for pipeline and guidance, and commentary on the franchise's exposure to competitive entrants and patent horizon. As a single metric ahead of the full print, the signal is partial.